Damora Therapeutics, Inc. (GLTO) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
Building 23
Boston, MA 02453
United States of America (the)
Phone
457 070 5210
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
7
First IPO Date
October 28, 2020
| Name | Title | Pay | Year Born |
| Hans T. Schambye | Co-Founder, President, Chief Executive Officer & Director | 1.03M | 1966 |
| Lori C. Firmani | Chief Financial Officer | 446,528 | 1974 |
| Becker Hewes | Chief Medical Officer | 528,064 | 1967 |
| Garrett Winslow | Senior Vice President, General Counsel & Corporate Secretary | 734,792 | 1980 |
| Matthew Kronmiller | EVice President of Strategy & Chief Business Officer | 0 | 1988 |
| Ulf J. Nilsson | Co-Founder | 0 | N/A |
| Sherwin Sattarzadeh | Interim Principal Executive Officer & COO | 0 | N/A |
| Hakon Leffler | Co-Founder | 0 | N/A |
| Tariq Sethi FRCP | Co-Founder | 0 | N/A |
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.